LXX Chart by TradingView

Business Description

Lexaria Bioscience Corp. (“Lexaria”, “Company”) is a life sciences company that has recently received patent protection for their DehydraTECH™ technology from the U.S. Patent and Trademark Office.

Website: https://www.lexariabioscience.com/

FRC Analyst's Reports

Lexaria Bioscience (CSE: LXX) Focus Seemingly on R&D as Licensing Revenues Slow May. 7, 2019
Lexaria Bioscience (CSE: LXX) Landmark Partnership with Tobacco Titan Feb. 5, 2019
Lexaria (CSE: LXX) Additional Licensees and Expanded IP Aug. 31, 2018
Lexaria (OTCQX: LXRP / CSE: LXX) Initial Cannabis Focus; Multi-Market Potential Jan. 12, 2018


Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy Jul. 22, 2021
Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3 Jul. 21, 2021
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada’s National Research Council Jul. 15, 2021
Lexaria Receives Patent Protection in Japan Jul. 13, 2021
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets Jul. 5, 2021